|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 449.16 USD | -1.06% |
|
+1.46% | +90.88% |
| 11-13 | Worldwide Healthcare improves in first-half; sees lower final dividend | AN |
| 11-10 | Alnylam Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 10:15 AM |
Business description: Alnylam Pharmaceuticals, Inc.
Number of employees: 2,230
Sales by Activity: Alnylam Pharmaceuticals, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Discovery, Development and Commercialization of Rnai Therapeutics | 493M | 844M | 1.04B | 1.83B | 2.25B |
Geographical breakdown of sales: Alnylam Pharmaceuticals, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States | 194M | 325M | 473M | 689M | 934M |
Europe | 120M | 260M | 315M | 399M | 516M |
Rest of World | 47.06M | 77.03M | 107M | 153M | 196M |
Executive Committee: Alnylam Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 31/12/2021 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 57 | 12/08/2019 |
| Chief Tech/Sci/R&D Officer | - | 31/03/2023 | |
Piyush Sharma
CMP | Compliance Officer | - | 20/09/2022 |
Pushkal Garg
CTO | Chief Tech/Sci/R&D Officer | 57 | 28/10/2014 |
Composition of the Board of Directors: Alnylam Pharmaceuticals, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 79 | 22/04/2012 |
Amy Schulman
CHM | Chairman | 64 | 04/01/2023 |
Michael Bonney
CHM | Chairman | 66 | 30/11/2015 |
David Pyott
BRD | Director/Board Member | 71 | 17/12/2015 |
| Director/Board Member | 62 | 27/10/2021 | |
Colleen Reitan
BRD | Director/Board Member | 65 | 31/05/2018 |
Margaret Hamburg
BRD | Director/Board Member | 69 | 09/01/2019 |
| Director/Board Member | 69 | 01/03/2020 | |
Charles Sigal
BRD | Director/Board Member | 73 | 21/08/2022 |
Carolyn Bertozzi
BRD | Director/Board Member | 58 | 04/01/2023 |
Company details: Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street Henri A. Termeer Square
02142, Cambridge
+617 551 8200
http://www.alnylam.com
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.06% | +1.46% | +74.15% | +110.40% | 59.98B | |
| +0.38% | +10.92% | +30.40% | +187.95% | 916B | |
| +0.35% | +5.02% | +29.01% | +13.97% | 470B | |
| +0.03% | +6.02% | +36.98% | +53.13% | 411B | |
| -1.31% | +6.59% | +9.37% | -8.49% | 314B | |
| +0.28% | +4.90% | +31.48% | +24.51% | 276B | |
| -1.25% | +2.37% | +12.61% | +32.51% | 256B | |
| -0.01% | +7.70% | -5.53% | -7.40% | 231B | |
| -2.39% | +6.82% | -58.60% | -24.69% | 221B | |
| +0.22% | +5.17% | +13.79% | +18.03% | 181B | |
| Average | -0.30% | +5.81% | +17.37% | +39.99% | 333.52B | |
| Weighted average by Cap. | -0.14% | +7.11% | +19.27% | +64.67% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALNY Stock
- Company Alnylam Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition